Tags : Modifiers

Genentech Signs an Exclusive Option and License Agreement with Skyhawk

Tuba Khan July 17, 2019

Shots: Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing […]readmore

Biotech

Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers

Tuba Khan May 7, 2019

Shots: Skyhawk to receive upfront, milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to […]readmore

Tags : Modifiers

Genentech Signs an Exclusive Option and License Agreement with Skyhawk

Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Modifiers

Genentech Signs an Exclusive Option and License Agreement with Skyhawk

Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company